We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    RCS-01
Previous Study | Return to List | Next Study

Study of Intradermal Injections of RCS-01 in Male and Female Subjects

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02391935
First Posted: March 18, 2015
Last Update Posted: October 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
JensonR+ Limited
PHARMALOG Institut für klinische Forschung GmbH
Syreon Corporation
Innovacell Biotechnologie AG
Datinf GmbH
Information provided by (Responsible Party):
RepliCel Life Sciences, Inc.
  Purpose

The primary purpose of this study is to assess the safety profile of RCS-01 injections as compared to placebo injections. This study will also measure the impact these injections will have on skin markers related to aging through evaluation of gene expression profiles.

30 participants will be selected for this study based on their health status, current/past medications, and ability to adhere to protocol-related requirements. At the first visit and after providing informed consent, participants are evaluated against the study inclusion/exclusion criteria and provide blood samples for screening assessments (including virology). If suitable for study participation, participants will provide a biopsy from the scalp from which RCS-01 will be prepared and will have four treatment evaluation sites identified on their buttocks, two on each side.

Study participants will be randomized to one of two treatment subgroups. Participants in the RCS-01 Subgroup (n=24) will receive injections of RCS-01 or placebo or a 'sham' injection (a needle penetration without injection of liquid). Participants in the the Placebo Subgroup (n= 6) will be randomized to receive only injections of placebo or sham injections.

Baseline evaluations of subjects' overall health and skin condition at treatment sites on their buttocks will be performed before receipt of injections at Day 0. In addition to injections delivered at Day 0, the pre-selected treatment evaluation sites will receive intradermal injections of RCS-01 or placebo (cryomedium) or a sham injection four (4) and eight (8) weeks after Day 0 according to a randomization schedule for a total of three (3) injections per treatment site.

All participants will return to the clinic for at least 9 visits during the 52-week follow-up period to monitor long-term safety. At the 12-week time point, 18 randomly-selected participants from the RCS-01 Subgroup will provide biopsies from all injection sites for analysis of skin markers related to aging. At the 26-week time point, the remaining participants will provide biopsies of all injection sites for histopathological analysis.


Condition Intervention Phase
Intrinsic Aging of Skin Skin Wrinkling Solar Degeneration of Skin Drug: RCS-01 Drug: Placebo Device: Sham injection Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Placebo-controlled, Single-centre, Phase I Safety Study of Intradermal Injections of RCS-01 in Male and Female Subjects (50 to 65 Years Old)

Further study details as provided by RepliCel Life Sciences, Inc.:

Primary Outcome Measures:
  • Incidence of local adverse events [ Time Frame: 52 weeks after first injection ]
    Within-patient comparison of the local (reported at treatment evaluation sites) adverse event profile between treatment evaluation sites treated with RCS-01 or placebo. The local adverse event profile is defined by the incidence, relationship to treatment, severity and seriousness of adverse events reported at the treatment evaluation sites.


Secondary Outcome Measures:
  • Incidence of adverse events [ Time Frame: 52 weeks after first injection ]
    Between-subject comparison of the systemic (not reported at treatment evaluation sites) adverse event profile between participants in the RCS-01 Subgroup versus Placebo Subgroup.

  • Incidence of abnormalities in skin structure [ Time Frame: 52 weeks after first injection ]
    A within-patient and between patient comparison of histology results from analyses performed on biopsies obtained from treatment evaluation sites.

  • Incidence of changes in markers related to skin aging [ Time Frame: 12 weeks after first injection ]
    Markers to be assessed include fibrillar collagen type I (COL 1A1, COL 1A2) and type III (COL 3A1), transforming growth factor beta1, connective tissue growth factor, matrix metalloproteinases 1, 3 and 9, tissue inhibitor of matrix metalloproteinase 1 and lumican . Incidence of changes within- and between-participants.


Enrollment: 17
Actual Study Start Date: October 10, 2015
Study Completion Date: July 12, 2017
Primary Completion Date: July 12, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: RCS-01
Cultured, autologous hair follicle cells suspended in cryomedium
Drug: RCS-01
Cultured, autologous hair follicle cells suspended in cryomedium
Drug: Placebo
Cryomedium
Device: Sham injection
skin penetration of the needle without injection of liquid
Placebo Comparator: Placebo
cryomedium
Drug: Placebo
Cryomedium
Device: Sham injection
skin penetration of the needle without injection of liquid

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or female Caucasian in good health between the age of 50 and 65 years.
  2. Female subjects must be post-menopausal for at least one year or surgically sterile.
  3. Signed and dated informed consent and willingness to attend all study visits and complete all procedures required by this protocol.
  4. The treatment evaluation sites are of uniform skin color without erythema, dark pigmentation or scars that may confound study results.

Exclusion Criteria:

  1. Any transient skin disorder or infections (e.g. pyoderma, tinea corporis, contact or irritative dermatitis, scleroderma etc.) within 20 cm of the treatment evaluation sites or the presence of tattoos near the treatment sites.
  2. Subjects diagnosed with psoriasis, lichen planus, vitiligo, systemic scleroderma, or lupus erythematosus.
  3. Any condition that, in the investigator's opinion, would impact subject's safety and/or a subject's ability to complete all study related procedures.
  4. History of infection with or positive serology results for human immunodeficiency virus (HIV), hepatitis B or C, or syphilis.
  5. Presence/history of hypertrophic scars and/or keloids.
  6. Subjects diagnosed with cancer with or without chemotherapy treatment within 3 years prior enrollment.
  7. Women who are pregnant or nursing.
  8. Current use of any medications not permitted in the study
  9. Ongoing or recent participation in a cosmetic and/or clinical research study prior to enrolment.
  10. Subject not agreeing to avoid UV exposure (sun, solarium) on the nude buttocks during the study period.
  11. Known allergy or hypersensitivity to human serum albumin, DMSO, gentamicin, material of bovine origin and/or local anesthetics.
  12. Close affiliation with the investigational site (e.g., a close relative of the investigator or a possibly dependent person (e.g., employee or student of the investigational site)).
  13. Subjects diagnosed with coagulopathies or significant thrombocytopenia
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02391935


Locations
Germany
IUF Leibniz-Institut für umweltmedizinische Forschung gGmbH
Düsseldorf, Germany, 40225
Sponsors and Collaborators
RepliCel Life Sciences, Inc.
JensonR+ Limited
PHARMALOG Institut für klinische Forschung GmbH
Syreon Corporation
Innovacell Biotechnologie AG
Datinf GmbH
Investigators
Principal Investigator: Alessandra Marini, MD IUF Leibniz-Institut für umweltmedizinische Forschung gGmbH
  More Information

Additional Information:
Responsible Party: RepliCel Life Sciences, Inc.
ClinicalTrials.gov Identifier: NCT02391935     History of Changes
Other Study ID Numbers: RCS-01-001-2014
First Submitted: March 12, 2015
First Posted: March 18, 2015
Last Update Posted: October 11, 2017
Last Verified: October 2017

Keywords provided by RepliCel Life Sciences, Inc.:
Chronic Effect of Ultraviolet Radiation on Normal Skin (Photo-aging)